In preparation for the upcoming MAX I FER I MAN clinical study targeting iron deficiency in men, and the future launch of our Semaglutide microneedle patch for obesity, we are proud to announce the launch of our new website for QUIA – NZI Ltd.

We are now preparing to launch a study similar to the FEMININ study currently being conducted at BIO VITOS PHARMA for women—this time at QUIA – NZI Ltd, focused on men. The new study will be called MAX I FER I MAN.

The study is scheduled to begin in September 2025, pending final approval from the Ethics Committee, just as we previously received for the women’s study at BIO VITOS PHARMA. The study is expected to be completed by the end of 2025.

It will be led by Jamshaid, under the supervision of Professor Fredrik Nyström, following the same clinical and scientific model as the ongoing FEMININ study.

Professor Fredrik Nyström is a senior physician and professor of internal medicine at Linköping University, widely recognized for his research in metabolism, nutrition, and lifestyle-related diseases. He has published extensively and is highly regarded in both academic and public health spheres.

Approximately 13% of all men suffer from low levels of iron in their blood, a frequently underdiagnosed condition. Treating iron deficiency in men can lead to significantly improved energy, cognitive performance, endurance, heart health, and general quality of life. It also plays an important role in reducing the risk of chronic fatigue and metabolic disorders.

The market potential is considerable. Millions of men globally are affected by low iron levels, creating a strong and expanding demand for proven, accessible solutions. The MAXIFERIMAN study aims to provide the clinical foundation for such treatments, targeting an underserved and health-critical segment of the population.

Following the successful completion of the study, QUIA – NZI Ltd is planning to list on the London Stock Exchange Main Market in 2026.

The London Stock Exchange (LSE) is one of the world’s most respected capital markets, offering global visibility and access to institutional investors. Its Main Market is home to established companies that meet high standards of governance, transparency, and financial performance. For a life science company like QUIA – NZI Ltd, listing on the LSE enhances credibility and provides access to deep and diverse sources of capital.

If the results of MAX I FER I MAN are successful and commercial potential is confirmed, a future listing on the New York Stock Exchange (NYSE)—in line with the plans for BIO VITOS PHARMA—will also be considered.

The New York Stock Exchange (NYSE) is the largest and most prestigious stock exchange in the world. Known for its stringent regulatory standards and unparalleled liquidity, the NYSE provides listed companies with exceptional global exposure and access to some of the world’s leading institutional investors.

For a pharmaceutical company, listing on the NYSE brings a wide range of benefits, including enhanced global credibility, access to U.S. capital markets, increased valuation potential, and the ability to attract strategic partnerships within the U.S. healthcare ecosystem. It also offers a strong platform for long-term growth, especially for companies addressing large, unmet medical needs with scientifically validated solutions.

With MAX I FER I MAN underway, a solid regulatory and clinical foundation, and a clear roadmap to LSE—and potentially NYSE—listing, QUIA – NZI Ltd is well-positioned to emerge as a leading innovator in men’s health and iron deficiency treatment.